Drug Trial Radar · NCT05489705
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,700
Planned (sponsor's estimate)
Start
Aug 16, 2022
Primary completion
Aug 17, 2029
Study completion Aug 17, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting. Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
MavacamtenDrug
As per product label
Non-mavacamten symptomatic oHCM therapyDrug
Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatmentTime frame: Up to 5 Years
- Change in resting left ventricular outflow tract (LVOT) gradient from baselineTime frame: Up to 18 months
Locations
101 sites in 9 countries. Site status is shown where the registry gives one.
Alaska Heart Institute
Anchorage, Alaska · Recruiting
Pima Heart and Vascular
Tucson, Arizona · Recruiting
UAMS
Little Rock, Arkansas · Recruiting
Local Institution - 0037
La Jolla, California · Active not recruiting
Keck School of Medicine of USC-Usc
Los Angeles, California · Recruiting
Stanford Health Care Hospital & Clinics
Palo Alto, California · Recruiting
University Of California San Francisco Medical Center
San Francisco, California · Recruiting
UC Denver, AMC
Aurora, Colorado · Recruiting
Local Institution - 0067
Hartford, Connecticut · Active not recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Local Institution - 0065
Jacksonville, Florida · Active not recruiting
Local Institution - 0046
Honolulu, Hawaii · Active not recruiting
University of Chicago Dept of Medicine
Chicago, Illinois · Recruiting
Indiana. University
Indianapolis, Indiana · Recruiting
Franciscan Physician Network-Indiana Heart Physicians
Indianapolis, Indiana · Recruiting
Local Institution - 0045
Iowa City, Iowa · Active not recruiting
Local Institution - 0059
Baltimore, Maryland · Active not recruiting
MedStar Health Research Institute
Baltimore, Maryland · Recruiting
Harvard (Massachusetts General Hospital)
Boston, Massachusetts · Recruiting
Harvard Medical School - Brigham and Women's Hospital (BWH)
Boston, Massachusetts · Recruiting
Spectrum Health Medical Group
Grand Rapids, Michigan · Recruiting
Henry Ford Health System
West Bloomfield, Michigan · Recruiting
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota · Recruiting
Cardiology Associates Research, Llc
Tupelo, Mississippi · Recruiting
St. Luke's Mid-America Heart Institute
Kansas City, Missouri · Recruiting
Local Institution - 0033
Kansas City, Missouri · Active not recruiting
Washington University
St Louis, Missouri · Recruiting
CHI Health Reseach Center
Omaha, Nebraska · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Local Institution - 0026
Morristown, New Jersey · Active not recruiting
Bassett Medical Center
Cooperstown, New York · Recruiting
Local Institution - 0009
New York, New York · Active not recruiting
Mount Sinai Hospital
New York, New York · Recruiting
Saint Francis Hospital
Roslyn, New York · Recruiting
WMCHealth Advanced Physician Services
Valhalla, New York · Recruiting
Focus Clinical Research
Charlotte, North Carolina · Recruiting
Duke University Health System
Durham, North Carolina · Recruiting
Christ Hospital Health Network
Cincinnati, Ohio · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Local Institution - 0003
Cleveland, Ohio · Active not recruiting
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.